XXXX in @entity0 survivors: a difficult survivorship issue.

@entity172 @entity1 @entity251 @entity0 @entity2133 @entity2494 @entity5932 @entity3941 @entity111 @entity2670 @entity546
Management of @entity0 includes systematic therapies including chemotherapy and endocrine therapy can lead to a variety of symptoms that can impair the quality of life of many @entity0 survivors. @entity3941 , caused by decreased levels of circulating @entity172 to urinary and vaginal receptors, is commonly experienced by this group. Chemotherapy induced @entity2670 and endocrine therapies including aromatase inhibitors and selective @entity172 receptor modulators can trigger the onset of @entity3941 or exacerbate existing symptoms. Symptoms of @entity3941 include @entity2133 , @entity546 , and irritation of genital skin, @entity111 , burning, vaginal discharge, and soreness. The diagnosis of @entity3941 is confirmed through @entity1 -reported symptoms and gynecological examination of external structures, @entity5932 . Lifestyle modifications can be helpful but are usually insufficient to significantly improve symptoms. Non-hormonal vaginal therapies may provide additional relief by increasing vaginal moisture and fluid. Systemic @entity172 therapy is contraindicated in @entity0 survivors. Continued investigations of various treatments for @entity3941 are necessary. Local @entity172 -based therapies, @entity2494 , @entity251 , and pH-balanced gels continue to be evaluated in ongoing studies. Definitive results are needed pertaining to the safety of topical @entity172 in @entity0 survivors.
